注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
XTL Biopharmaceuticals Ltd是一家生物制药公司,致力于收购和开发用于治疗自身免疫性疾病的药物。该公司在研对象包括hCDR1系统性红斑狼疮和重组人促红细胞生成素(rHuEPO)多发性骨髓瘤。其hCDR1是系统性红斑狼疮(SLE)和干燥综合征(SS)的潜在治疗方法。hCDR1是皮下施用的肽(短蛋白),并且充当疾病特异性治疗以修饰SLE相关的自身免疫过程。rHuEPO已知贫血药物,可延长患者的生存期,用于治疗多发性骨髓瘤血癌。其促红细胞生成素(EPO)是主要由肾脏产生的糖蛋白激素。促红细胞生成素通过与红细胞祖细胞表面的受体结合,促进其增殖和分化,并维持其活力,从而促进红细胞生成。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Daniel J. Wallace | - | - | Member of Clinical Advisory Board |
Osnat Hillel Fain | 55 | 2015 | Independent Non-Executive & External Director |
Murray Urowitz | - | - | Member of Clinical Advisory Board |
Robert I. Fox | - | 2017 | Member of Clinical Advisory Board |
Lee S. Simon | 70 | - | Member of Clinical Advisory Board |
Simon Bowman | - | 2017 | Member of Clinical Advisory Board |
David Isenberg | - | 2015 | Member of Clinical Advisory Board |
Jonathan Schapiro | 61 | 2014 | Non-Executive Director |
Shlomo Spokone Shalev | 59 | 2014 | CEO & Director |
Doron Turgeman | 53 | 2014 | Non-Executive Chairman of the Board |
Alexander Rabinovich | 51 | 2017 | Non-Executive Director |
Dobroslav Melamed | 46 | 2014 | Independent Non-Executive Director |
Iris Shapira Yalon | 56 | 2020 | Independent Non-Executive & External Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核